The expression of aphidicolin-induced fragile sites in familial breast cancer patients.

2.50
Hdl Handle:
http://hdl.handle.net/10541/100386
Title:
The expression of aphidicolin-induced fragile sites in familial breast cancer patients.
Authors:
Mitchell, Erika L D; Woodhouse, Brian; Birch, Jillian M; Santibanez-Koref, Mauro F
Abstract:
The expression frequency of aphidicolin-induced fragile sites was examined in familial breast cancer patients to determine whether this parameter could be used as a marker of genetic susceptibility in at-risk individuals. No difference was found in expression frequency between the breast cancer patients and a group of normal individuals (p = 0.61). This indicates that the expression frequency of aphidicolin-induced fragile sites is not a suitable marker for assessing genetic susceptibility in familial breast cancer.
Affiliation:
CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, United Kingdom.
Citation:
The expression of aphidicolin-induced fragile sites in familial breast cancer patients. 1993, 67 (2):108-12 Cancer Genet. Cytogenet.
Journal:
Cancer Genetics and Cytogenetics
Issue Date:
Jun-1993
URI:
http://hdl.handle.net/10541/100386
DOI:
10.1016/0165-4608(93)90161-E
PubMed ID:
8392434
Type:
Article
Language:
en
ISSN:
0165-4608
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMitchell, Erika L Den
dc.contributor.authorWoodhouse, Brianen
dc.contributor.authorBirch, Jillian Men
dc.contributor.authorSantibanez-Koref, Mauro Fen
dc.date.accessioned2010-06-07T10:49:41Z-
dc.date.available2010-06-07T10:49:41Z-
dc.date.issued1993-06-
dc.identifier.citationThe expression of aphidicolin-induced fragile sites in familial breast cancer patients. 1993, 67 (2):108-12 Cancer Genet. Cytogenet.en
dc.identifier.issn0165-4608-
dc.identifier.pmid8392434-
dc.identifier.doi10.1016/0165-4608(93)90161-E-
dc.identifier.urihttp://hdl.handle.net/10541/100386-
dc.description.abstractThe expression frequency of aphidicolin-induced fragile sites was examined in familial breast cancer patients to determine whether this parameter could be used as a marker of genetic susceptibility in at-risk individuals. No difference was found in expression frequency between the breast cancer patients and a group of normal individuals (p = 0.61). This indicates that the expression frequency of aphidicolin-induced fragile sites is not a suitable marker for assessing genetic susceptibility in familial breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAphidicolin-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating-
dc.subject.meshCells, Cultured-
dc.subject.meshChromosome Fragile Sites-
dc.subject.meshChromosome Fragility-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.titleThe expression of aphidicolin-induced fragile sites in familial breast cancer patients.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, United Kingdom.en
dc.identifier.journalCancer Genetics and Cytogeneticsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.